Glucose intolerance during hormonal therapy for prostate cancer.

Glucose intolerance during hormonal therapy for prostate cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Glucose intolerance during hormonal therapy for prostate cancer. Abstract Text:

K Suzuki,A Nukui,Y Hara,T Morita,

The aim of this study was to examine the influence of hormonal therapy (HT) on glucose metabolism in prostate cancer (PCa) patients. Fifty-two PCa patients receiving HT with gonadotropin-releasing hormone (GnRH) analogues and/or antiandrogen drugs were enrolled in this study. Both blood and urine samples were taken a few hours after breakfast before and after HT, and glucose levels in the blood and urine were measured. Elevations of blood glucose levels of 30-50, 50-100 and over 100 mg/dl after HT as compared with the levels before HT were observed in two, eight and five patients, respectively. Urine examination revealed deterioration of glucosuria in seven patients. The mean blood glucose level after HT was significantly higher than that measured before HT. The elevation of blood glucose level significantly correlated with concurrence of diabetes mellitus (DM) and higher body mass index (BMI) before HT. Deterioration of glucosuria significantly correlated with the concurrence of DM. HT for PCa patients, especially with concurrent DM or obesity, induces elevation of the blood glucose level and deterioration of glucosuria. Therefore, glucose intolerance should be considered during HT for PCa.Prostate Cancer and Prostatic Diseases (2007) 10, 384-387; doi:10.1038/sj.pcan.4500976; published online 8 May 2007.

Glucose intolerance during hormonal therapy for prostate cancer. Publishing Authors By Initials

K Suzuki,A Nukui,Y Hara,T Morita,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Glucose intolerance during hormonal therapy for prostate cancer. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Prostate cancer and prostatic diseases

VOLUME: 10

Page Numbers: 384-7

Journal Abbreviation: Prostate Cancer Prostatic Dis.

ISSN: 1365-7852

DAY: 8

MONTH: 05

YEAR: 2007

Glucose intolerance during hormonal therapy for prostate cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9815755

Glucose intolerance during hormonal therapy for prostate cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Glucose intolerance during hormonal therapy for prostate cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Glucose intolerance during hormonal therapy for prostate cancer.

AFFILIATION: [1] 1Department of Urology, Jichi Medical University, Tochigi, Japan [2] 2Department of Urology, Utsunomiya Shakaihoken Hospital, Tochigi, Japan.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Prostate Cancer Prostatic Dis

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Glucose intolerance during hormonal therapy for prostate cancer Related Publications

• Association between experience of stressful life events and muscle-related temporomandibular disorders in patients seeking free treatment in a dental hospital.
• Cerebral hemodynamics during microgravity.
• Characterization of Lactococcus garvieae isolated from radish and broccoli sprouts that exhibited a KG+ phenotype, lack of virulence and absence of a capsule.
• Cryptadines A and B, novel C(27)N(3)-type pentacyclic alkaloids from Lycopodium cryptomerinum.
• Degradation of arylarsenic compounds by microorganisms.
• Development of a fully automatic scheme for detection of masses in whole breast ultrasound images.
• Efficacy, safety, and cost effectiveness of intravenous midazolam and flunitrazepam for primary insomnia in terminally ill patients with cancer: a retrospective multicenter audit study.
• Features and feedback: enhancing metamnemonic knowledge at retrieval reduces source-monitoring errors.
• Fusion of single-photon emission computed tomography and computed tomography images of sentinel lymph nodes in extramammary Paget's disease of the scrotum.
• Gait analysis in an osteoarthritis patient with restoration of the hip joint space following contralateral total hip arthroplasty: a case report.
• Glucose intolerance during hormonal therapy for prostate cancer.
• High salt culture conditions inhibit serum- and NGF- but not PMA-induced Egr-1 gene transcription in rat C6 glioma cells.
• Identification and characterization of RNA-dependent RNA polymerase activity in recombinant Japanese encephalitis virus NS5 protein.
• Molecular dynamics analysis of interfacial structures and sum frequency generation spectra of aqueous hydrogen halide solutions.
• Novel functions of herbal medicines in dendritic cells: role of amomi semen in tumor immunity.
• Plastic alteration of vestibulo-cardiovascular reflex induced by 2 weeks of 3-G load in conscious rats.
• Polygoacetophenoside, A New Acetophenone Glucoside from Polygonum multiflorum1.
• Pordamacrines A and B, alkaloids from Daphniphyllum macropodum.
• Preferential recognition of a microbial metabolite by human Vgamma2Vdelta2 T cells.
• Protein kinase CK2 is a key activator of histone deacetylase in hypoxia-associated tumors.
• Range of motion measurement of an artificial hip joint using CT images.
• Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells.
• Snake venom components affecting blood coagulation and the vascular system: structural similarities and marked diversity.
• Taxodistines A and B, abietane-type diterpenes from Taxodium distichum.
• Tobacco smoke causes premature skin aging.
• Transforming growth factor-beta stimulates IL-1beta-induced monocyte chemoattractant protein-1 expression in human synovial cells via the ERK/AP-1 pathway.
• [Pericardial cyst]
• [Protective role of HO-1 in oxidative tissue injuries]
• [Recent changes in the incidence of life-threatening events in the operating room: JSA surveys between 2001 and 2005]
• [Resection of cancer of the cardia enabled by combined treatment with S-1 and paclitaxel after esophageal stenting for impaired patency complicating stage IV gastric cancer - a case report]